Skip to main content

Table 1 Patient and Treatment Characteristics

From: Capecitabine and stereotactic radiation in the management of breast cancer brain metastases

Variable

n

%

No. of Patients

23

 

Treatment Sessions

31

 

No. of Lesions

90

 

F/U from RT (months)

 Median (range)

9.2 (1.9–94.1)

 

F/U from Brain Metastases Diagnosis (months)

 Median (range)

20.2 (5.5–96.4)

 

Age at time of RT

 Median (range)

56 (40–75)

 

KPS

 100

7

30%

 90

8

35%

 80

7

30%

 60

1

4%

Lesions Treated Per Patient

 Median (range)

3 (1–12)

 

Receptor Status

 HR+/HER2-

7

30%

 HR- /HER2+

3

13%

 HR+/HER2+

6

26%

 HR−/HER2-

7

30%

RT in Relation to Capecitabine

 Before

12

39%

 After

4

13%

 Concurrent

15

48%

Interval Between Capecitabine and RT (months)

 Median (range)

1.5 (0.26–5.5)

 

Concurrent Therapy with Capecitabine

 None

7

30%

 Additional Chemotherapy

8

35%

 Trastuzumab

2

9%

 Trastuzumab + Chemotherapy

2

9%

 Trastuzumab + TKI

2

9%

 Pembrolizumab

1

4%

 TKI

1

4%

  1. Abbreviations: F/U follow-up, RT radiation therapy, KPS Karnofsky performance status, TKI tyrosine kinase inhibitor